- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07443436
Immunmodulerende behandling av interstitiell lungesykdom assosiert med surfaktantrelaterte genvarianter (TIPS)
Immunmodulerende behandling av interstitiell lungesykdom assosiert med surfaktantrelaterte genvariasjoner
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
- tolerance of the triple therapy,
- correlation between the respiratory, radiological and clinical functional response,
- quality of life of the patients,
- overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
- Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
- Thoracic CT scan and PFT at 6 months and one year after randomization
- Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
- Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Annabelle METOIS
- Telefonnummer: 0140257939
- E-post: annabelle/metois@aphp.fr
Studer Kontakt Backup
- Navn: BORIE Raphaël
- E-post: raphael.borie@aphp.fr
Studiesteder
-
-
-
Bron, Frankrike, 69500
- Pneumologie Louis Pradel
-
Ta kontakt med:
- COTTIN Vincent
- E-post: vincent.cottin@chu-lyon.fr
-
Lille, Frankrike, 59037
- Pneumologie Institu Coeur Poumon
-
Ta kontakt med:
- WEMEAU Lidwine
- E-post: lidwibne.wemeau@chru-lille.fr
-
Rennes, Frankrike, 35033
- Pneumologie Pontchaillou
-
Ta kontakt med:
- JOUNEAU Stéphane
- E-post: stephane.jouneau@chu-rennes.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years and <80 years
- Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
- ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years
Exclusion Criteria:
- Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
- Pregnancy and breastfeeding
- Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
- Desire to have a child within 22 months
- Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
- Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
- No affiliation to any health insurance system
- Refusal to participate to the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
The experimental treatment will be the combination of:
|
Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no |
|
Aktiv komparator: Standard of care
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in forced vital capacity decline between the 2 groups at one year.
Tidsramme: 12 Months
|
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene. |
12 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
tolerance of the triple therapy
Tidsramme: 12 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization) |
12 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Tidsramme: 12 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization |
12 months
|
|
Quality of life of the patients
Tidsramme: 12 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization, |
12 months
|
|
tolerance of the triple therapy
Tidsramme: 6 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
6 months
|
|
tolerance of the triple therapy
Tidsramme: 3 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
3 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Tidsramme: 6 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization |
6 months
|
|
Quality of life of the patients
Tidsramme: 9 months
|
Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization, |
9 months
|
|
Quality of life of the patients
Tidsramme: 6 months
|
Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization, |
6 months
|
|
Quality of life of the patients
Tidsramme: 3 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization, |
3 months
|
|
Overall survival
Tidsramme: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Transplant-free survival
Tidsramme: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Exacerbation free-survival
Tidsramme: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Hospitalization-free survival
Tidsramme: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
tolerance of the triple therapy
Tidsramme: 9 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), |
9 months
|
|
tolerance of the triple therapy
Tidsramme: 12 months
|
ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients) |
12 months
|
|
tolerance of the triple therapy
Tidsramme: 12 months
|
Ophthalmological (at one year after randomization) |
12 months
|
|
tolerance of the triple therapy
Tidsramme: 9 months
|
ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients) |
9 months
|
|
tolerance of the triple therapy
Tidsramme: 6 months
|
ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients) |
6 months
|
|
tolerance of the triple therapy
Tidsramme: 3 months
|
ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) |
3 months
|
|
Overall survival
Tidsramme: 9 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization |
9 months
|
|
Overall survival
Tidsramme: 6 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization |
6 months
|
|
Overall survival
Tidsramme: 3 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization |
3 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i luftveiene
- Lungesykdommer
- Lungesykdommer, interstitielle
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Polysykliske forbindelser
- Gravadienes
- Gravaner
- Steroider
- Smeltede ringforbindelser
- Makrolider
- Laktoner
- Gravadienedioler
- Kinoliner
- Aminoquinolines
- Erytromycin
- Polyketider
- Klorokin
- Prednison
- Hydroksyklorokin
- Azitromycin
Andre studie-ID-numre
- APHP251230
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .